Sabby Management’s Bone Biologics BBLG Stock Holding History

Sabby Management’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-225	Closed	-$15.5K	–	89
2023 Q2	$15.5K	Sell	225 -817	-78%	-$214K	0.01%	85
2023 Q1	$388K	Buy	1,042 +183	+21%	+$76.4K	0.34%	27
2022 Q4	$259K	Buy	+859	New	+$484K	0.23%	44

Other funds holding BBLG

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's BBLG Position: Q3 2023 in Review

Sabby Management sold out of Bone Biologics (BBLG) in Q3 2023, closing a stake of 225 shares — an estimated $15.5K sold.

Sabby Management first reported a position in BBLG in Q4 2022 and held it in 3 quarters. The position peaked at $388K in Q1 2023. 7 funds tracked by Wall St. Rank hold BBLG as of Q3 2023.

Sabby Management reported no remaining Bone Biologics position as of Q3 2023 after selling out during the quarter.
Sabby Management sold 225 Bone Biologics shares in Q3 2023, an estimated $15.5K.
Sabby Management first reported a position in Bone Biologics in Q4 2022 and held it in 3 quarters.
Sabby Management's Bone Biologics position peaked at $388K in Q1 2023.
7 funds tracked by Wall St. Rank held Bone Biologics as of Q3 2023.

Based on Sabby Management's 13F filing for Q3 2023, filed 14 Nov 2023.